Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT 2: tepotinib plus osimertinib in MET-amplified EGFR-mutant NSCLC after acquired resistance to osimertinib
CTR20192589Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Apr 2020; status: completed.
02
Drugs
tepotinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20192589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192589.